|
|
Volumn 292, Issue 3, 2004, Pages 317-318
|
|
Are OTC statins ready for prime time?
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CHOLESTEROL;
HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;
LIPID;
LOW DENSITY LIPOPROTEIN CHOLESTEROL;
MEVINOLIN;
PRAVASTATIN;
SIMVASTATIN;
NON PRESCRIPTION DRUG;
CARDIOVASCULAR DISEASE;
CARDIOVASCULAR RISK;
CLINICAL TRIAL;
DRUG COST;
DRUG EFFICACY;
DRUG INDUSTRY;
DRUG SAFETY;
DRUG USE;
FOOD AND DRUG ADMINISTRATION;
HUMAN;
MORBIDITY;
MORTALITY;
MYOPATHY;
PRESCRIPTION;
PRIORITY JOURNAL;
REVIEW;
UNITED KINGDOM;
ARTICLE;
DRUG LEGISLATION;
UNITED STATES;
DRUGS, NON-PRESCRIPTION;
GREAT BRITAIN;
HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS;
LEGISLATION, DRUG;
UNITED STATES;
|
|
EID: 3142701478
PISSN: 00987484
EISSN: None
Source Type: Journal
DOI: 10.1001/jama.292.3.317 Document Type: Review |
|
Times cited : (5)
|
|
References (0)
|